TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01054300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 2 mg split into twice daily
Description: Ertugliflozin 1 mg dose (1 mg strength tablet) administered twice daily x 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 4 mg single dose
Description: Ertugliflozin 4 mg dose (four 1 mg strength tablets), administered as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 4 mg single dose
Description: Ertugliflozin 4 mg dose (four 1 mg strength tablets), administered as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 4 mg split into twice daily
Description: Ertugliflozin 2 mg dose (two 1 mg strength tablets) administered twice daily x 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 4 mg split into twice daily
Description: Ertugliflozin 2 mg dose (two 1 mg strength tablets) administered twice daily x 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to ertugliflozin administered as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to ertugliflozin administered as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to ertugliflozin administered as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to ertugliflozin administered as a single dose
Study: NCT01614782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5823
Description: MK-5823 administered subcutaneously (doses ranging from 0.35 mg to 2.8 mg) once daily for 3 weeks. Doses may be adjusted downward based on safety, tolerability, and/or pharmacokinetic data. The decision to dose escalate will be based on accrued safety/tolerability data at the prior dose level.~In each arm, 6 participants will be randomized to receive study drug and 2 participants will be randomized to receive placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5823
Description: MK-5823 administered subcutaneously (doses ranging from 0.35 mg to 2.8 mg) once daily for 3 weeks. Doses may be adjusted downward based on safety, tolerability, and/or pharmacokinetic data. The decision to dose escalate will be based on accrued safety/tolerability data at the prior dose level.~In each arm, 6 participants will be randomized to receive study drug and 2 participants will be randomized to receive placebo.
Study: NCT01715337

Intervention type: OTHER
Group type: OTHER
Intervention: pulmonary rehabilitation
Description: 3-week rehabilitation including exercise training, breathing therapy, psychosocial support, medical treatment etc.
Study: NCT01614782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5823
Description: MK-5823 administered subcutaneously (doses ranging from 0.35 mg to 2.8 mg) once daily for 3 weeks. Doses may be adjusted downward based on safety, tolerability, and/or pharmacokinetic data. The decision to dose escalate will be based on accrued safety/tolerability data at the prior dose level.~In each arm, 6 participants will be randomized to receive study drug and 2 participants will be randomized to receive placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5823
Description: MK-5823 administered subcutaneously (doses ranging from 0.35 mg to 2.8 mg) once daily for 3 weeks. Doses may be adjusted downward based on safety, tolerability, and/or pharmacokinetic data. The decision to dose escalate will be based on accrued safety/tolerability data at the prior dose level.~In each arm, 6 participants will be randomized to receive study drug and 2 participants will be randomized to receive placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5823
Description: MK-5823 administered subcutaneously (doses ranging from 0.35 mg to 2.8 mg) once daily for 3 weeks. Doses may be adjusted downward based on safety, tolerability, and/or pharmacokinetic data. The decision to dose escalate will be based on accrued safety/tolerability data at the prior dose level.~In each arm, 6 participants will be randomized to receive study drug and 2 participants will be randomized to receive placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5823
Description: MK-5823 administered subcutaneously (doses ranging from 0.35 mg to 2.8 mg) once daily for 3 weeks. Doses may be adjusted downward based on safety, tolerability, and/or pharmacokinetic data. The decision to dose escalate will be based on accrued safety/tolerability data at the prior dose level.~In each arm, 6 participants will be randomized to receive study drug and 2 participants will be randomized to receive placebo.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to MK-5823 administered subcutaneously once daily for 3 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to MK-5823 administered subcutaneously once daily for 3 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to MK-5823 administered subcutaneously once daily for 3 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to MK-5823 administered subcutaneously once daily for 3 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to MK-5823 administered subcutaneously once daily for 3 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to MK-5823 administered subcutaneously once daily for 3 weeks.
Study: NCT03324516

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Re-Suspension of the temporal muscle after a craniotomy.
Description: The temporal muscle cuff will be used to re-suspend the temporal muscle after a traditional craniotomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional re-suspension of the temporal muscle
Description: The temporal muscle will be re-suspended to the bone plate that is used to fixate the temporal bone that is removed for the craniotomy.
Study: NCT02100670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% diclofenac sodium plus 3% menthol
Description: To be applied four times daily for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% diclofenac sodium plus 0.09% menthol
Description: To be applied four times daily for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% menthol
Description: To be applied four times daily for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with 0.09% menthol gel
Description: To be applied four times daily for 10 days.
Study: NCT02047994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple therapy
Description: Participants who are positive with Helicobacter pylori in Group1 will receive triple therapy.~* Esomeprazole 40 mg bid for 10 days~* Clarithromycin 500 mg bid for 10 days~* Amoxicillin 1000 mg bid for 10 days
Study: NCT00536549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guardian RT

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education about the self monitoring blood glucose
Study: NCT00811317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop
Description: Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target
Study: NCT01282164

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glucagon stimulation test and insulin tolerance test
Description: glucagon stimulation test using 1 mg (1.5 mg if weigh \>90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test in subjects with type 2 diabetes mellitus (T2DM), coronary artery disease (CAD), cerebrovascular disease (CVD), seizure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: glucagon stimulation test and insulin tolerance test
Description: glucagon stimulation test using 1 mg (1.5 mg if weigh \>90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test in subjects with type 2 diabetes mellitus (T2DM), coronary artery disease (CAD), CVD (cerebrovascular disease), seizure
Study: NCT03339726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New Formulation Phenylephrine HCl
Description: 2 doses of one tablet 12 hours apart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Phenylephrine HCl
Description: 4 doses of one capsule 4 hours apart

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 doses of placebo capsule and tablet taken 4 hours apart
Study: NCT02530411

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: The pharmacology and mode of action studies established that fulvestrant is the first agent in a new class of anti-estrogens that down-regulate the estrogen receptor (ER), and can therefore be described as an ER down-regulator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: The pharmacology and mode of action studies established that fulvestrant is the first agent in a new class of anti-estrogens that down-regulate the estrogen receptor (ER), and can therefore be described as an ER down-regulator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: Vandetanib is a potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptor (VEGFR; also known as kinase insert domain containing receptor)-2, an endothelial cell receptor for vascular endothelial growth factor (VEGF), and also possesses activity against epidermal growth factor receptor (EGFR) and Rearranged during Transfection (RET) tyrosine kinases.
Study: NCT01103453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Action Planning Supermarket (VAP-S) Software
Description: The VAP-S simulates a supermarket with multiple aisles displaying items. Several obstacles are designed to hinder the progression of the shopper along the aisles. In addition, virtual humans populate the supermarket. The VAP-S is designed so that the user enters the supermarket behind the cart and navigates within the supermarket via the keyboard keys. He is thus able to experience the environment personally without any intermediate. The task is to purchase 7 items from a list, proceed to the cashier and pay for them.~We propose 9 sessions of 45 minutes. The results will be analyzed to develop goals for intervention, together with the client to study his awareness of his performance of IADL and Executive functions and to enhance his motivation to participate in the intervention.
Study: NCT03808324

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic investigations
Description: Participants will undergo tests and diagnostics investigations to identify signs of chronic rejection after heart transplantation.
Study: NCT02339116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoruracil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoruracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT02348398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 600 mg by mouth daily in a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: 0.25 mg by mouth daily for 21 days of a 28 day cycle.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Call
Description: During follow up if disease gets worse, participant called by study staff every 3 months. Each call should last about 5 minutes.
Study: NCT02339116

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Study: NCT03852368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The effects of exercise with different intensity on the executive functions of adolescents

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The effects of exercise with different intensity on the executive functions of adolescents

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The effects of exercise with different intensity on the executive functions of adolescents
Study: NCT03316417

Intervention type: OTHER
Intervention: Renal Tolerance to Immunotherapy
Description: The main objective is to describe the renal tolerance of these innovative therapies within a population homogeneous of patients.
Study: NCT00674323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verteporfin Photodynamic Therapy
Description: After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, light application of 50 J/cm\^2 to the study eye was begun 15 minutes after the start of infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verteporfin Photodynamic Therapy
Description: After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, light application of 50 J/cm\^2 to the study eye was begun 15 minutes after the start of infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab at dose of 0.5 mg administered as an intravitreal injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab at dose of 0.5 mg administered as an intravitreal injection.
Study: NCT03609125

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBS eyedrop
Description: The product is dispensed as sterile frozen vials containing 0.8 ml of product for the daily administration. The product is thawed and administered at a dose of 1 drop / 8 times each eye during the waking period.
Study: NCT04806230

Intervention type: DRUG
Intervention: sertraline, mirtazapine, venlafaxine, citalopram, escitalopram
Description: Naturalistic treatment
Study: NCT03623932

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: immunosuppressor/TNFalpha
Description: Standard Treatment : immunosuppressor/TNFalpha as in standard practice

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: 8 hypnosis group sessions during 2 months
Study: NCT01200537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: This group of patients will receive estradiol patches prior to the IVF cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Contraceptive Pills (OCP)
Description: This group of patients will receive OCP's prior to the IVF cycle.
Study: NCT03535402

Intervention type: DRUG
Group type: OTHER
Intervention: Sarilumab
Description: SC administration of 200 mg twice a week
Study: NCT02144948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: e.-coli-nissle
Description: 1 ml qd for 24 weeks
Study: NCT00172081

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Daily subcutaneous injection with placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALX1-11
Description: PTH (1-84) 100 mcg injected subcutaneously into the thigh or abdomen
Study: NCT03804190

Intervention type: OTHER
Intervention: questionaire
Description: dutch musculoskeletal questionaire

Intervention type: OTHER
Intervention: questionaire
Description: dutch musculoskeletal questionaire

Intervention type: OTHER
Intervention: questionaire
Description: dutch musculoskeletal questionaire

Intervention type: OTHER
Intervention: questionaire
Description: dutch musculoskeletal questionaire
Study: NCT04394507

Intervention type: DIAGNOSTIC_TEST
Intervention: Near-Infrared Fluorescence imaging
Description: .Near-infrared imaging was used to evaluate the function of the superficial lymphatic vessels in the right lower leg and foot as previously described.doi: 10.1161/CIRCIMAGING.118.008074.

Intervention type: DIAGNOSTIC_TEST
Intervention: Near-Infrared Fluorescence imaging
Description: .Near-infrared imaging was used to evaluate the function of the superficial lymphatic vessels in the right lower leg and foot as previously described.doi: 10.1161/CIRCIMAGING.118.008074.

Intervention type: DIAGNOSTIC_TEST
Intervention: Strain Gauge Plethysmography
Description: Strain Gauge Plethysmography to asses capillary filtration rate og the lower limb

Intervention type: DIAGNOSTIC_TEST
Intervention: Strain Gauge Plethysmography
Description: Strain Gauge Plethysmography to asses capillary filtration rate og the lower limb
Study: NCT02803567

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief psycho-educational intervention
Description: Participants in the intervention arm will receive a computerized brief intervention composed of tailored feedback and psycho-education specific to their chronic condition.
Study: NCT01446263

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radial access versus femoral access for coronary angiography and intervention
Description: Radial access or femoral access for coronary angiography and intervention in patients with prior coronary artery bypass grafts

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radial access versus femoral access for coronary angiography and intervention
Description: Radial access or femoral access for coronary angiography and intervention in patients with prior coronary artery bypass grafts
Study: NCT02576782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perineural Dexamethasone and bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic Dexamethasone plus perineural bupivacaine

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: intravenous saline plus perineural bupivacaine
Study: NCT00543400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M118
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M118
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M118
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated Heparin
Description: IV infusion
Study: NCT00748124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PleuraSeal Sealant System
Description: Lung Sealant Device + standard tissue closing techniques (sutures/staples)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard Tissue Closure Techniques
Description: Standard tissue closure techniques (sutures/ staples) alone

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Tissue Closure Techniques
Description: Standard tissue closure techniques (sutures/ staples) alone
Study: NCT01584492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclomethasone+formoterol 50/6 (1 inhalation)
Description: CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 1535 50/6 (2 inhalations)
Description: CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 1535 50/6 (4 inhalations)
Description: CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol + Beclomethasone dipropionate
Description: * Formoterol HFA pMDI 6 µg / actuation~* Extrafine BDP HFA pMDI 50 µg/actuation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (6 inhalations)
Description: Matched placebo via pMDI
Study: NCT02342665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (BAY80-6946)
Description: Dosing is weekly for the first 3 weeks (on Days 1, 8, and 15) of a 28-day cycle, followed by a 1-week break (i.e., no infusion on Day 22).
Study: NCT04192513

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: J. lividum
Description: Investigational Product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: J. lividum
Description: Investigational Product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: J. lividum
Description: Investigational Product
Study: NCT03384953

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Hypnosis - Group Treatment
Description: group treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Hypnosis - Individual Treatment
Description: individual treatment
Study: NCT01406145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP0777
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP0777
Description: oral tablet
Study: NCT02618720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ornidazole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02922790

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard health information
Description: Subjects will review standard health information

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard health information plus info. on DNA damage
Description: Subjects will review standard health information and information on DNA damage

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Subjects will review standard health information and information on DNA damage, plus pictures of their DNA damage
Description: Subjects will review standard health information and information on DNA damage, as well as review pictures of their cells' DNA damage
Study: NCT01855581

Intervention type: DRUG
Intervention: pediatric sedation (propofol, ketamine, etc)
Description: Presedation assessment was performed by hospitalists and pediatric sedation was performed by protocol in the sedation unit.~Data on demographics, primary illness, ASA, snoring history, URI symptom, medications used, procedure and recovery times, medication doses, outcomes of anesthesia, airway interventions and adverse events were collected retrospectively.
Study: NCT02211534

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Electromagnetic Field Device (Provant)
Description: The PEMF device delivers non-thermal, non-ionizing pulsed electromagnetic energy to the target tissue, using 27.12 megahertz pulses lasting 42 microseconds and delivered 1000 times per second. The system generates an electromagnetic field that is continuously monitored and regulated to ensure consistent dosing. The therapeutic electromagnetic field is delivered by means of an applicator pad that is placed against the treatment site. The active and sham devices will be identical in appearance and all other physical characteristics in order to maintain the masking of the treatment.